MOBIDIAG-LTD.
9.10.2019 08:02:12 CEST | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the CE-IVD marking of the Novodiag® Stool Parasites test, a comprehensive and cost-effective molecular diagnostic test for the detection of intestinal parasites directly from stool samples.
Tuomas Tenkanen, CEO of Mobidiag, said, “Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labor-intensive and require a high level of skill. Our Novodiag® Stool Parasites test is the only fully automated, rapid, cost-effective and easy to use diagnostic solution that can identify a comprehensive range of parasitic targets, for use in laboratories and hospitals.”
“Novodiag® Stool Parasites is the fourth test on our Novodiag® platform and, together with our Novodiag® C. difficile , Novodiag® Bacterial GE+ and Novodiag® CarbaR+ tests, further strengthens our offering in the detection of gastrointestinal infections. With our complementary Amplidiag® and Novodiag® solutions, we continue to offer a range of highly versatile combined solutions enabling the broad application of molecular diagnostics around the world.”
Novodiag® Stool Parasites combines real-time PCR and microarray technologies to allow cost-effective, rapid and comprehensive detection of >95% of intestinal parasites. This syndromic test is designed to run on-demand using the automated Novodiag® system and is able to detect the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. The test provides complete results in 90 minutes with less than five minutes hands-on time by an operator.
While most infections and death from parasitic diseases affect people in developing countries, increasing incidence in developed nations combined with a shortage of microscopy trained hospital staff are driving demand for this test.
The Novodiag® Stool Parasites test is now available directly through Mobidiag and local distributors. For more information, visit https://mobidiag.com/products/novodiag/#stoolparasites
About Novodiag®
Stool Parasites
Novodiag®
Stool Parasites is an automated qualitative nucleic acid-based diagnostic test for detecting the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. It is part of the Novodiag®
platform, Mobidiag’s fully automated molecular testing platform for diagnostics of infectious diseases and antibiotic resistances. Combining real-time PCR and microarray technologies, Novodiag®
platform allows direct analysis of a patient sample placed in a disposable cartridge for comprehensive screening of multiple or single pathogens. In addition of Novodiag®
C. difficile
, Novodiag®
Bacterial GE+ and Novodiag®
CarbaR+, we launch a new test, the Novodiag®
Stool Parasites which complements our offer for gastrointestinal infections. Our panel covers >95% of stool parasites.
About Mobidiag Ltd.
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adaptability for large scale manufacturing, Mobidiag’s Amplidiag®
and Novodiag®
platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s intial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.
Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005570/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The 2026 NAB Show Wraps with Proof the Future of Media and Entertainment is Expanding Beyond Broadcasting23.4.2026 01:52:00 CEST | Press release
The Show’s growing community of creators, enterprise media teams and leaders in sports media is driving the next era of storytelling The 2026 NAB Showwrapped today, welcoming more than 58,000 registered attendees and reaffirming its place at the center of the global media and entertainment evolution. Driven by an expanding community of creators, enterprise media teams and leaders in sports media, the Show has brought in new audiences and sparked new collaborations. The 2026 NAB Show didn’t just reflect where the industry is; it pushed it forward, strengthening its status as the must-attend marketplace for the future of storytelling and content innovation. “The 2026 NAB Show captured the energy and transformation driving today’s media and entertainment landscape, unveiling powerful new tools and technologies that put storytelling in everyone’s hands,” said Karen Chupka, executive vice president of NAB Show. “This year, we brought together a truly global community to spark innovation, el
ASP Announces Strategic Partnership With ChemDAQ to Advance Safety, Confidence, and Compliance in Sterile Processing23.4.2026 01:42:00 CEST | Press release
Advanced Sterilization Products (ASP), a global leader in infection prevention and low‑temperature sterilization, today announced a strategic partnership with ChemDAQ, a leading provider of hazardous gas detection and monitoring solutions. Together, ASP and ChemDAQ will support healthcare organizations by strengthening safety practices, reinforcing regulatory confidence, and advancing best‑in‑class sterile processing environments. As part of this partnership, ASP and ChemDAQ collaborated on evidence rooted in industry engagement and thought leadership to help sterile processing professionals stay ahead of evolving standards and guidance, including AAMI ST58 and other recommendations related to sterilant exposure and workplace safety. These efforts underscore ASP’s commitment to continuous improvement and practical innovation that meets real‑world needs. This collaboration reflects ASP’s role as a trusted advisor to sterile processing professionals, bringing together proven low‑temperat
TSMC Debuts A13 Technology at 2026 North America Technology Symposium22.4.2026 21:00:00 CEST | Press release
Newest Node Pushes Density Scaling and Energy Efficiency to New Heights to Address Industry’s Most Demanding Applications TSMC (TWSE: 2330, NYSE: TSM) today debuted its latest innovation in its most advanced process technology at the Company’s 2026 North America Technology Symposium. TSMC’s new A13 process is a direct shrink of its industry-leading A14 node announced in 2025, enabling even more compact and efficient designs to address insatiable customer demand in computational requirements for next-generation artificial intelligence, high-performance computing (HPC), and mobile applications. Representing TSMC’s commitment to continuous improvement, A13 provides 6% area savings from A14. Design rules are fully backward compatible with A14, enabling customers to quickly migrate their designs to TSMC’s latest nanosheet transistor technology. In addition, A13 delivers increased power efficiency and performance gains through design-technology co-optimization, and is scheduled to enter prod
Galderma Shareholders Approve All Annual General Meeting Proposals22.4.2026 17:45:00 CEST | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions. Shareholders approved the election of Harry Kirsch as independent member of the Board of Directors, as well as the election of Samuel du Retail and Delphine Viguier-Hovasse, representatives of L’Oréal, as non-independent members of the Board. In addition, Thomas Ebeling (Chair), Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy and Dr. Flemming Ørnskov were re-elected to the Board. The AGM also approved the company’s 2025 Annual Financial Statements, Non-Financial Report and Compensation Report. Detailed voting results and the official minutes will be published on Galderma's
Altrove and Bloomineral Named Winners of the 2026 Grand Prix ACF AutoTech22.4.2026 15:21:00 CEST | Press release
IoT.Bzh receives the inaugural Industrialization Prize at the 9th edition of the international automotive startup competition Altrove and Bloomineral have been crowned winners of the 2026 Grand Prix ACF AutoTech, the international startup competition recognizing the best of automotive innovation. The ninth edition was held on Wednesday, April 15 at the Automobile Club de France in Paris, where IoT.Bzh also received the first-ever Industrialization Prize. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422236542/en/ Picture of the end of the event with the winners : Bloomineral, Altrove and Iot.Bzh + all the Jury Members from French Automotive OEM and Tier1 Hosted by competition founder Richard de Cabrol and Simon Degiovanni, the evening gathered more than 250 leaders from the automotive, technology, digital, business and media sectors, with attendees joining both on-site and online. Six finalist startups, selected from mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom